

Press Release
November 22, 2021

Scandion Oncology announces share purchase by Board of Directors and Executive Management

Scandion Oncology A/S, the Cancer Drug Resistance Company, today announced that members of the Board of Directors and Executive Management have purchased shares in the company.

The following share purchases have been reported:

		Shares purchased	Total shareholding
Peter Høngaard Andersen	Chairman of the Board	6,500	59,565
Jørgen Bardenfleth	Vice-chairman of the Board	15,000	425,629
Christian Vinding Thomsen	Board member	10,000	10,000
Thomas Feldthus	Board member	10,000	28,182
Martin Møller	Board member	4,700	4,700
Bo Rode Hansen	Board member & CEO	2,042	42,442
Annie Rasmussen	Employee representative	1,205	20,000

Persons under an obligation to report are defined as members of the Board of Directors and members of Executive Management.

For further information regarding Scandion Oncology, please contact:

Bo Rode Hansen, President & CEO

Phone: +45 3810 2017

E-mail: info@scandiononcology.com

Website: www.scandiononcology.com

The information was provided by the contact person above for publication on November 22, 2021, at 17.30 CET.

Scandion Oncology A/S is a clinical Phase II biotechnology company currently developing first-in-class, oral add-on drugs to existing market leading anti-cancer therapies. As add-on to standard anti-cancer therapies, it introduces an effective treatment approach for cancer, which is or has become resistant to cancer-fighting drugs. Scandion Oncology is listed on Nasdaq First North Growth Market Sweden.

Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.